Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.47 |
| ▸ | CES1 | P23141 | 3/20 | 0.47 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formaldehyde SCHEMBL25437128 | 0.98 | CES2 (0.46) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL20268270 | 0.81 | CES2 (0.53) | CES2CES1ACKR3RAB9ANPC1 | |
| SCHEMBL3892255 | 0.81 | CES2 (0.53) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL29788741 | 0.81 | CES2 (0.53) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL25437126 | 0.81 | CES2 (0.49) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL20628934 | 0.77 | CES2 (0.47) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL20628901 | 0.77 | CES2 (0.52) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL6945770 | 0.74 | CES2 (0.52) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL30115025 | 0.74 | CES2 (0.52) | CES2CES1SNCAACKR3L3MBTL1 | |
| SCHEMBL26317015 | 0.73 | CES2 (0.47) | CES2CES1SNCAACKR3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028322-A1 | PREPARATION METHOD FOR INTERMEDIATE COMPOUND ACTING AS SYNTHETIC POSACONAZOLE, AND INTERMEDIATE COMPOUND PREPARED THEREBY | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4495107-A1 | PREPARATION METHOD FOR INTERMEDIATE COMPOUND ACTING AS SYNTHETIC POSACONAZOLE, AND INTERMEDIATE COMPOUND PREPARED THEREBY | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023173717-A1 | PREPARATION METHOD FOR INTERMEDIATE COMPOUND ACTING AS SYNTHETIC POSACONAZOLE, AND INTERMEDIATE COMPOUND PREPARED THEREBY | 浙江奥翔药业股份有限公司 | 2023-09-21 | — | — | WO | disclosed |
| CN-114591272-A | Preparation method of intermediate compound for synthesizing posaconazole and intermediate compound prepared by same | 浙江奥翔药业股份有限公司 | 2022-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260028322-A1 | PREPARATION METHOD FOR INTERMEDIATE COMPOUND ACTING AS SYNTHETIC POSACONAZOLE, AND INTERMEDIATE COMPOUND PREPARED THEREBY | ERG28, CYP2F1, VKORC1 | CES2 343/4885CES1 19/4885SNCA 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.